MA41203B1 - Procédés pour la préparation d'un composé diaryl-thiohydantoïne - Google Patents

Procédés pour la préparation d'un composé diaryl-thiohydantoïne

Info

Publication number
MA41203B1
MA41203B1 MA41203A MA41203A MA41203B1 MA 41203 B1 MA41203 B1 MA 41203B1 MA 41203 A MA41203 A MA 41203A MA 41203 A MA41203 A MA 41203A MA 41203 B1 MA41203 B1 MA 41203B1
Authority
MA
Morocco
Prior art keywords
preparation
processes
compound
diaryl
thiohydantoin compound
Prior art date
Application number
MA41203A
Other languages
English (en)
Other versions
MA41203A (fr
Inventor
Cyril Ben Haim
Andras Horvath
Johan Erwin Edmond Weerts
Jennifer Albaneze-Walker
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MA41203A publication Critical patent/MA41203A/fr
Publication of MA41203B1 publication Critical patent/MA41203B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0237—Amines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255—Phosphorus containing compounds
    • B01J31/0267—Phosphines or phosphonium compounds, i.e. phosphorus bonded to at least one carbon atom, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, the other atoms bonded to phosphorus being either carbon or hydrogen
    • B01J31/0268—Phosphonium compounds, i.e. phosphine with an additional hydrogen or carbon atom bonded to phosphorous so as to result in a formal positive charge on phosphorous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/61—Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/32—Addition reactions to C=C or C-C triple bonds
    • B01J2231/321—Hydroformylation, metalformylation, carbonylation or hydroaminomethylation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202—Polynuclearity
    • B01J2531/0205—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

L'invention concerne des procédés et des intermédiaires pour la préparation d'un composé (x), qui est actuellement à l'étude pour le traitement du cancer de la prostate.
MA41203A 2014-12-19 2015-12-17 Procédés pour la préparation d'un composé diaryl-thiohydantoïne MA41203B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094425P 2014-12-19 2014-12-19
PCT/US2015/066345 WO2016100645A1 (fr) 2014-12-19 2015-12-17 Procédés pour la préparation d'un composé diaryl-thiohydantoïne
EP15828426.5A EP3233823B1 (fr) 2014-12-19 2015-12-17 Procédés pour la préparation d'un composé diaryl-thiohydantoïne

Publications (2)

Publication Number Publication Date
MA41203A MA41203A (fr) 2017-10-25
MA41203B1 true MA41203B1 (fr) 2019-05-31

Family

ID=55221505

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41203A MA41203B1 (fr) 2014-12-19 2015-12-17 Procédés pour la préparation d'un composé diaryl-thiohydantoïne

Country Status (34)

Country Link
US (3) US10316015B2 (fr)
EP (1) EP3233823B1 (fr)
JP (2) JP6696986B2 (fr)
KR (1) KR102586087B1 (fr)
CN (2) CN111620849B (fr)
AR (1) AR103230A1 (fr)
AU (2) AU2015364612B2 (fr)
BR (1) BR112017013093B1 (fr)
CA (1) CA2970933C (fr)
CY (1) CY1121722T1 (fr)
DK (1) DK3233823T3 (fr)
EA (1) EA029666B1 (fr)
ES (1) ES2719616T3 (fr)
HR (1) HRP20190583T1 (fr)
HU (1) HUE042349T2 (fr)
IL (2) IL252844B (fr)
LT (1) LT3233823T (fr)
MA (1) MA41203B1 (fr)
MD (1) MD3233823T2 (fr)
ME (1) ME03354B (fr)
MX (2) MX383748B (fr)
NZ (1) NZ732756A (fr)
PH (2) PH12022550923A1 (fr)
PL (1) PL3233823T3 (fr)
PT (1) PT3233823T (fr)
RS (1) RS58428B1 (fr)
SG (2) SG10201907094QA (fr)
SI (1) SI3233823T1 (fr)
SM (1) SMT201900207T1 (fr)
TR (1) TR201904788T4 (fr)
TW (3) TWI690520B (fr)
UA (1) UA122404C2 (fr)
WO (1) WO2016100645A1 (fr)
ZA (1) ZA201704878B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383748B (es) * 2014-12-19 2025-03-14 Aragon Pharmaceuticals Inc Procesos para la preparación de un compuesto de diariltiohidantoína.
US11285153B2 (en) 2017-09-29 2022-03-29 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidine piperazine compound and use thereof
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
US12606539B2 (en) 2020-09-04 2026-04-21 Synthon B.V. Process for preparation of apalutamide
CN114621109B (zh) * 2020-12-14 2024-04-26 成都苑东生物制药股份有限公司 一种阿帕他胺的合成方法及其中间体
CN115650954A (zh) * 2022-10-24 2023-01-31 江苏海悦康医药科技有限公司 阿帕他胺有关物质的制备方法
CN116082246B (zh) * 2022-12-31 2023-11-21 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
WO2011084402A1 (fr) * 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase
EP3124481B1 (fr) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Modulateurs de récepteur d'androgène et utilisations associées
ES2940901T3 (es) * 2013-05-29 2023-05-12 Hinova Pharmaceuticals Inc Compuesto de imidazol dicetona y uso del mismo
CN103896847B (zh) 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
MX383748B (es) * 2014-12-19 2025-03-14 Aragon Pharmaceuticals Inc Procesos para la preparación de un compuesto de diariltiohidantoína.
LT3233803T (lt) * 2014-12-19 2019-04-10 Aragon Pharmaceuticals, Inc. Diariltiohidantoino junginio gamybos būdas

Also Published As

Publication number Publication date
WO2016100645A1 (fr) 2016-06-23
SG10201907094QA (en) 2019-09-27
TWI690520B (zh) 2020-04-11
US10723714B2 (en) 2020-07-28
CN107108553B (zh) 2020-04-28
PH12022550923A1 (en) 2023-01-23
TW201632509A (zh) 2016-09-16
JP2020143070A (ja) 2020-09-10
US11040953B2 (en) 2021-06-22
CN111620849B (zh) 2023-11-14
MA41203A (fr) 2017-10-25
ME03354B (fr) 2019-10-20
CN107108553A (zh) 2017-08-29
TW202016086A (zh) 2020-05-01
EA029666B1 (ru) 2018-04-30
CY1121722T1 (el) 2020-07-31
SI3233823T1 (sl) 2019-04-30
CA2970933C (fr) 2023-10-10
HUE042349T2 (hu) 2019-06-28
EP3233823B1 (fr) 2019-01-30
US20190135775A9 (en) 2019-05-09
TWI768716B (zh) 2022-06-21
TWI731512B (zh) 2021-06-21
AU2015364612A1 (en) 2017-07-06
MX383748B (es) 2025-03-14
BR112017013093A2 (pt) 2018-02-20
MX2017008178A (es) 2018-03-06
IL252844A0 (en) 2017-08-31
NZ732756A (en) 2023-02-24
SMT201900207T1 (it) 2019-05-10
PL3233823T3 (pl) 2019-07-31
CA2970933A1 (fr) 2016-06-23
JP6696986B2 (ja) 2020-05-20
HRP20190583T1 (hr) 2019-05-17
IL252844B (en) 2021-03-25
IL281292A (en) 2021-04-29
KR102586087B1 (ko) 2023-10-05
TR201904788T4 (tr) 2019-04-22
SG11201704970RA (en) 2017-07-28
JP2018507170A (ja) 2018-03-15
IL281292B2 (en) 2023-07-01
LT3233823T (lt) 2019-04-10
RS58428B1 (sr) 2019-04-30
KR20170098870A (ko) 2017-08-30
EA201791391A1 (ru) 2017-10-31
TW202124372A (zh) 2021-07-01
UA122404C2 (uk) 2020-11-10
PT3233823T (pt) 2019-05-20
MX2019012734A (es) 2019-12-05
ZA201704878B (en) 2019-02-27
US20200354334A1 (en) 2020-11-12
AU2020227093A1 (en) 2020-09-24
EP3233823A1 (fr) 2017-10-25
DK3233823T3 (en) 2019-04-08
US10316015B2 (en) 2019-06-11
AR103230A1 (es) 2017-04-26
AU2015364612B2 (en) 2020-06-11
MD3233823T2 (ro) 2019-07-31
US20190284156A1 (en) 2019-09-19
BR112017013093B1 (pt) 2023-03-14
ES2719616T3 (es) 2019-07-11
CN111620849A (zh) 2020-09-04
US20180002309A1 (en) 2018-01-04
IL281292B1 (en) 2023-03-01
PH12017501151A1 (en) 2017-11-27

Similar Documents

Publication Publication Date Title
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP3397968A4 (fr) Inhibiteurs de l'antigène membranaire spécifique de la prostate (psma) à base d'urée, pour imagerie et traitement thérapeutique
NZ754731A (en) Azolopyrimidine for the treatment of cancer-related disorders
MX375467B (es) Proceso para la preparacion de un compuesto de diariltiohidantoina.
TN2020000072A1 (en) Psma ligands for imaging and endoradiotherapy
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201890068A1 (ru) Частицы диметилфумарата и фармацевтические композиции на их основе
NZ732208A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
EP3433239A4 (fr) Inhibiteur de type petite molécule de la translocation nucléaire du récepteur aux androgènes pour le traitement du cancer de la prostate résistant à la castration
EP3775171A4 (fr) Procédés de traitement d'un cancer résiduel minimal
PH12021551212A1 (en) Process for preparation of anthranilamides
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
MA51615A (fr) Polytherapie pour le traitement ou la prévention du cancer
MX2016015298A (es) Inhibidores de nampt y metodos.
EP3969001A4 (fr) Composés de bisfluoroalkyl-1,4-benzodiazépinone pour le traitement du cancer du sein activé par notch
EP3849544A4 (fr) Polythérapie pour le traitement du cancer de la prostate
MA54465A (fr) Inhibiteurs de cxcr7 destinés au traitement du cancer
EP3721993A4 (fr) Catalyseur pour le traitement d'oxychloration d'hydrocarbure, son procédé de préparation et procédé de préparation d'un composé oxychloré d'hydrocarbure l'utilisant
MA51614A (fr) Polythérapie pour le traitement ou la prévention du cancer